

14th European LUPUS Meeting



19 - 22 MARCH 2024
BRUGES, BELGIUM

PROGRAMME

Congress Chairs

Nathalie Costedoat-Chalumeau, Paris (FR)
Frédéric Houssiau, Brussels (BE)

Local Scientific Committee

Alain Cornet, Brussels (BE)
Véronique Le Guern, Paris (FR)
Christina Duesing, Düsseldorf (DE)
Farah Tamirou, Brussels (BE)

International Scientific Committee

Nancy Agmon-Levin, Tel-Hashomer (IL)	Chandra Mohan, Houston (US)
Marta Alarcon-Riquelme, Granada (ES)	Eric Morand, Melbourne (AU)
Zahir Amoura, Paris (FR)	Marta Mosca, Pisa (IT)
Jeanette Andersen, Lupus Europe	Daniel G. Oliveira, Porto (PT)
Hans-Joachim Anders, München (DE)	Ioannis Parodis, Stockholm (SE)
Martin Aringer, Dresden (DE)	Michelle Petri, Baltimore (US)
Laurent Arnaud, Strasbourg (FR)	Bernardo Pons-Estel, Rosario (AR)
Sang-Cheol Bae, Seoul (KR)	Ida Povilaite, Lupus Europe
George Bertsias, Heraklion (GR)	Anisur Rahman, London (UK)
Patrick Blanco, Bordeaux (FR)	Lars Rönnblom, Uppsala (SE)
Dimitrios Boumpas, Athens (GR)	Brad Rovin, Columbus (US)
Marina Botto, London (UK)	Guillermo Ruiz-Irastorza, Bizkaia (ES)
Ian Bruce, Manchester (UK)	Jane Salmon, New York (US)
Jill Buyon, New York (US)	Lucy Scarle, Lupus Europe
Ricard Cervera, Barcelona (ES)	Georg Schett, Erlangen (DE)
Eric Daugas, Paris (FR)	Matthias Schneider, Düsseldorf (DE)
Anne Davidson, New York (US)	Nan Shen, Shanghai (CN)
David D'Cruz, London (UK)	Luís Sousa Inês, Coimbra (PT)
Andrea Doria, Padua (IT)	Elisabet Svenungsson, Stockholm (SE)
Thomas Dörner, Berlin (DE)	Maria Tektonidou, Athens (GR)
Antoine Enfrein, Nantes (FR)	Angela Tincani, Brescia (IT)
Rebecca Fischer-Betz, Düsseldorf (DE)	Dalila Tremarias, Lupus Europe
Richard Furie, New York (USA)	Ronald van Vollenhoven, Amsterdam (NL)
Martin Herrmann, Erlangen (DE)	Carlos Vasconcelos, Porto (PT)
David Isenberg, London (UK)	Carola Vinuesa, London (UK)
Ana Malvar, Buenos Aires (AR)	Alexandre Voskuyl, Amsterdam (NL)
Xavier Mariette, Paris (FR)	Tim Vyse, London (UK)

Organising Secretariat

Medicongress Services NV
Noorwegenstraat 49
9940 Evergem, Belgium
Phone: +32 (0) 9 218 85 85
lupus24@medicongress.com
www.lupus24.be

Join us in Bruges!

Together with the International Scientific Committee members, we have the pleasure of inviting you to the **14th European Lupus Meeting**, taking place in Bruges, Belgium on 19 – 22 March 2024.

The 14th European Lupus Meeting intends to share the latest clinical and basic advances in the field of systemic lupus erythematosus with concurrent sessions combining invited talks and selected oral presentations. Furthermore a great debate, 8 fishbowl sessions and 2 poster sessions are scheduled.

We are proud that so many European and international experts will contribute to a first-class programme!

The 14th European Lupus Meeting will also be a unique opportunity to meet old friends and to make new ones.

Join us in Bruges and have a great time!



Frédéric Houssiau & Nathalie Costedoat-Chalumeau
Congress Chairs

16.00	Registration	
18.00	Opening Ceremony & Opening Lectures	Concert Hall
	Welcome Frédéric Houssiau & Nathalie Costedoat-Chalumeau Congress Chairs	
I1	What have been the major achievements in the field of lupus within the last decade and what is next? Eric Morand, Melbourne (AU)	
I2	Improving communication between lupus patients and physicians Lucy Scarle, Lupus Europe	
	Festive Opening of the Lupus 2024 Meeting	
19.30	Walking Dinner in the Foyer	

Parallel Sessions 1 & 2		
Session 1: Drug use in Real Life		Concert Hall
09.00	I3	Hydroxychloroquine: What's new? Nathalie Costedoat-Chalumeau, Paris (FR)
09.20	I4	Strategies to minimize glucocorticoids exposure Zahir Amoura, Paris (FR)
09.40	I5	Biologics in real life Alexandre Voskuyl, Amsterdam (NL)
10.00	O1	Impact of intravenous belimumab treatment on steroid use and disease activity in patients with systemic lupus erythematosus (SLE) in the US in clinical practice: 24-month results from the OBSERVE study Roger Levy, Collegeville (US)
10.10	O2	Serious infection, including severe COVID19, seems not to be a major clinical problem in patients with systemic lupus erythematosus treated with belimumab, according to the data from a large multicenter cohort Iñigo Rua-Figueroa, Las Palmas (ES)
10.20	O3	Physician experience influences glucocorticoid prescribing patterns in systemic lupus erythematosus (SLE): Results from the LUPHPOS survey Cristiana Sieiro Santos, León (ES)
10.30		Coffee Break
Session 2: Genetics		Chamber Music Room
09.00	I6	Cross ancestry analysis Tim Vyse, London (UK)
09.20	I7	SLE genetics update and clinical implication Sang-Cheol Bae, Seoul (KR)
09.40	I8	Gender Bias George Bertsias, Heraklion (GR)
10.00	O4	Clinical characteristics of patients with high SLE-specific and high multitrait polygenic risk – An investigation of SLE risk loci Nina Oparina, Uppsala (SE)
10.10	O5	Exploring the impact of genome-wide DNA methylation alterations on chromosome X inactivation and female lupus Olivia Castellini Pérez, Granada (ES)
10.20	O6	Epidemiology of moderate-to-severe SLE in Sweden Martina Frodlung, Linköping (SE)
10.30		Coffee Break

Parallel Sessions 3 & 4

Session 3: Pregnancy

Concert Hall

- 11.00 **I9** **Updates from the bench and bedside in neonatal lupus**
Jill Buyon, New York (US)
- 11.20 **I10** **Safety of new lupus drugs before and during pregnancy**
Rebecca Fischer-Betz, Düsseldorf (DE)
- 11.40 **I11** **What is still unclear in lupus pregnancy?**
Angela Tincani, Brescia (IT)
- 12.00 **O7** **High incidence of both spontaneous and indicated preterm birth in women with systemic lupus erythematosus: A systematic review and meta-analysis**
Birgit Blomjous, Amsterdam (NL)
- 12.10 **O8** **Hydroxychloroquine blood levels at first trimester of pregnancy and materno-fetal outcomes: A prospective study of 174 patients with systemic lupus erythematosus (GR2 study)**
Nathalie Costedoat-Chalumeau, Paris (FR)
- 12.20 **O9** **Early pregnancy exposure to hydroxychloroquine and preterm delivery in systemic lupus erythematosus**
Ngoc Viet Nguyen, Stockholm (SE)
- 12.30 **Lunch**
- 12.45 **Poster Session I**
- 13.30 **Satellite Symposium**

Session 4: Classification and Subsets

Chamber Music Room

- 11.00 **I12** **EULAR/ACR SLE classification criteria: 5 years later**
Martin Aringer, Dresden (DE)
- 11.20 **I13** **Subgrouping SLE patients: Is this the way forward?**
Elisabeth Svenungsson, Stockholm (SE)
- 11.40 **I14** **Use of molecular stratification to identify (non)-responders**
Marta Alarcon-Riquelme, Granada (ES)
- 12.00 **O10** **Ischemic stroke subtypes in SLE - Associations with a STAT4 risk genotype**
Elisabet Svenungsson, Stockholm (SE)
- 12.10 **O11** **Unsupervised machine-learning identifies distinct clusters based on B cell phenotyping and autoantibody profiles in patients with systemic lupus erythematosus**
Mariele Gatto, Turin (IT)
- 12.20 **O12** **Immune complexes containing anti-dsDNA in patients with systemic lupus erythematosus with renal involvement - Association with renal activity and response to treatment**
Iva Gunnarsson, Stockholm (SE)
- 12.30 **Lunch**
- 12.45 **Poster Session I**
- 13.30 **Satellite Symposium**

Parallel Sessions 5, 6 & 7

Session 5: Targeted Therapies

Concert Hall

- 14.30 **I15** **Targeting Type I IFN in SLE and lupus nephritis**
Richard Furie, New York (US)
- 14.50 **I16** **Targeting B cell lineage cells in SLE: From today's experience towards future possibilities**
Thomas Dörner, Berlin (DE)
- 15.10 **I17** **Choosing wisely: Which biological should we use in which patient?**
Ronald van Vollenhoven, Amsterdam (NL)
- 15.30 **O13** **Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study**
Panagiotis Garantziotis, Erlangen (DE)
- 15.40 **O14** **Rituximab Objective Outcome measures Trial in SLE (ROOTS): Outcomes of randomised and rescue rituximab therapy in a double-blind randomised placebo-controlled trial**
Edward Vital, Leeds (UK)
- 15.50 **O15** **B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separate neuropsychiatric systemic lupus erythematosus patients into two distinct subgroups with differential anticipated response to targeted therapies**
Julius Lindblom, Stockholm (SE)
- 16.00 **Coffee Break**

Session 6: Clinical Manifestations

Chamber Music Room

- 14.30 **I18** **Lupus enteritis**
David D'Cruz, London (UK)
- 14.50 **I19** **Autoinflammatory manifestations in SLE**
Carlos Vasconcelos, Porto (PT)
- 15.10 **I20** **Early events in neuropsychiatric lupus**
Dimitri Boumpas, Athens (GR)
- 15.30 **O16** **pQTL analysis of ficolin-3 activity reveals a link between the lectin pathway of complement and hematological disease manifestations in systemic lupus erythematosus**
Oskar Eriksson, Uppsala (SE)
- 15.40 **O17** **SLESIS-R: An improved score for prediction of serious infection in patients with systemic lupus erythematosus, developed from RELESSER prospective database cohort**
José María Pego-Reigosa, Vigo (ES)
- 15.50 **O18** **Data-driven clustering of cerebrospinal fluid proteome reflects clinical phenotypes of systemic lupus erythematosus**
Elsa Grenmyr, Lund (SE)
- 16.00 **Coffee Break**

Session 7: Patients' Session - Best Approaches to manage risks

Studio 1

- 14.30 **I21** **Hydroxychloroquine**
Nathalie Costedoat-Chalumeau, Paris (FR)
- 15.00 **I22** **Managing cardiovascular risk**
Christina Duesing, Düsseldorf (DE)
- 15.30 **I23** **Pregnancy with lupus**
Farah Tamirou, Brussels (BE)
- 16.00 **Coffee Break**

Parallel Sessions 8 & 9

Session 8: Outcome Measures

Concert Hall

- 16.30 **I24** **Defining the targets: Where do we stand?**
Andrea Doria, Padua (IT)
- 16.50 **I25** **Which is the optimal primary endpoint for lupus clinical trials?**
Luís Sousa Inês, Coimbra (PT)
- 17.10 **I26** **Ten tips for managing difficult lupus**
Guillermo Ruiz-Irastorza, Bizkaia (ES)
- 17.30 **O19** **Lupus low disease activity state and organ damage in relation to quality of life in SLE: A cohort study with up to 11 years of follow-up**
Christopher Sjöwall, Linköping (SE)
- 17.40 **O20** **Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials**
Diogo Jesus, Leiria (PT)
- 17.50 **O21** **Factors associated with SLE patient concordance to medication - Does nurse initiated therapy make a difference?**
Rosaria Salerno, London (UK)
- 18.00 **End of Day 1 and Guided Visit of the City**

Session 9: Pathophysiology of Lupus Nephritis

Chamber Music Room

- 16.30 **I27** **Cross species analysis of renal myeloid cells in lupus nephritis**
Anne Davidson, New York (US)
- 16.50 **I28** **Complement and kidney injury in lupus nephritis**
Brad Rovin, Columbus (US)
- 17.10 **I29** **OMICs insights on lupus nephritis chronicity**
Chandra Mohan, Houston (US)
- 17.30 **O22** **Interferon upregulation and B and plasma cell gene dysregulation patterns reveal three distinct lupus nephritis subgroups with differential anticipated response to targeted therapies**
Ioannis Parodis, Stockholm (SE)
- 17.40 **O23** **APOL1 genotype is a major determinant of lupus nephritis severity in patients of African ancestry**
Carole Burger, Paris (FR)
- 17.50 **O24** **Lupus podocytopathy: A rare form of lupus nephritis - An Italian retrospective multicenter study**
Grazia Dea Bonelli, Milano (IT)
- 18.00 **End of Day 1 and Guided Visit of the City**

08.00 Breakfast Meetings

Parallel Sessions 10 & 11

Session 10: Damage

Concert Hall

- 09.00 **I30** **Cardiovascular risk in SLE and APLS**
Maria Tektonidou, Athens (GR)
- 09.20 **I31** **Working towards a new SLE damage index**
Ian Bruce, Manchester (UK)
- 09.40 **I32** **Long-term follow-up of the University College London cohort**
Anisur Rahman, London (UK)
- 10.00 **O25** **First investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of children, adolescents, and young adults with juvenile-onset systemic lupus erythematosus**
Coziana Ciurtin, London (UK)
- 10.10 **O26** **Metabolite signature predicts subclinical atherosclerosis in Systemic Lupus Erythematosus (SLE)**
Elizabeth Jury, London (UK)
- 10.20 **O27** **Unveiling the impact of neuropsychiatric involvement in systemic lupus erythematosus on damage accrual**
Dionysis Nikolopoulos, Stockholm (SE)
- 10.30 **Coffee Break**

08.00 Breakfast Meetings

Session 11: Interferons and Innate Immunity

Chamber Music Room

- 09.00 **I33** **Type I IFN and immunometabolism in SLE**
Marina Botto, London (UK)
- 09.20 **I34** **The genetics of the IFN system in SLE**
Lars Rönnblom, Uppsala (SE)
- 09.40 **I35** **Inborn errors of innate immunity that instigate human lupus**
Carola Vinuesa, London (UK)
- 10.00 **O28** **Gut epithelial barrier dysfunction in lupus triggers a differential humoral response against commensals**
María Botía-Sánchez, Granada (ES)
- 10.10 **O29** **Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients**
Johan Rönnelid, Uppsala (SE)
- 10.30 **Coffee Break**

Parallel Sessions 12, 13 & 14

Session 12: Future Therapies

Concert Hall

- 11.00 **I36** **CAR T cell therapy in autoimmune diseases**
Georg Schett, Erlangen (DE)
- 11.20 **I37** **JAK inhibitors**
Ian Bruce, Manchester (UK)
- 11.40 **I38** **Immuno-organoids: A new tool for testing new drugs in autoimmune diseases**
Xavier Mariette, Paris (FR)
- 12.00 **O30** **How useful are the mouse models of lupus for clinical research and drug testing?**
María Rivas-Torrubia, Granada (ES)
- 12.10 **O31** **Impact of patient baseline characteristics on SLE Responder Index-4 (SRI4) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus**
Eric Morand, Melbourne (AU)
- 12.20 **O32** **Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis**
Richard Furie, New York (US)
- 12.30 **Lunch**
- 12.45 **Poster Session II**
- 13.30 **Satellite Symposium**

Session 13: Antiphospholipid Syndrome

Chamber Music Room

- 11.00 **I39** **Management of refractory APS**
Ricard Cervera, Barcelona (ES)
- 11.20 **I40** **Pregnancy in APS: New hopes on the horizon?**
Jane Salmon, New York (US)
- 11.40 **I41** **Cardiac manifestations in APS**
Nancy Agmon-Levin, Tel-Hashomer (IL)

- 12.00 **O33** **Plasma Thrombospondin-1 levels are associated with arterial and venous thrombotic events in systemic lupus erythematosus**
Marina Barguil Macedo, Seattle (US)
- 12.10 **O34** **Timing of thromboembolic events in systemic lupus erythematosus associated to Antiphospholipid Syndrome (APS); Results from a population-based study set in Norway**
Sigrid Reppe Moe, Oslo (NO)
- 12.30 **Lunch**
- 12.45 **Poster Session II**
- 13.30 **Satellite Symposium**

Session 14: Patients' Session - Lupus in Minorities

Studio 1

- 11.00 **I42** **Ethnicity**
Antoine Enfrein, Nantes (FR)
- 11.30 **I43** **Male with lupus**
George Bertsias (GR)
- 11.50 **I44** **Economically/socially less advantaged patients with lupus**
Daniel G. Oliveira, Porto (PT)
- 12.10 **O35** **HPV vaccination and cervical screening in SLE patients**
Marya Khan, London (UK)
- 12.20 **O36** **Male gender, educational level, disease activity, prednisone daily dose and previous medical adherence are predictive of medical adherence in systemic lupus erythematosus patients - Data from the Almenara Lupus Cohort**
Manuel Ugarte-Gil, Lima (PE)
- 12.30 **Lunch**
- 12.45 **Poster Session II**
- 13.30 **Satellite Symposium**

Parallel Sessions 15 & 16

Session 15: Treatment of Nephritis I

Concert Hall

- 14.30 **I45** **Treatment of lupus nephritis: Beyond recommendations**
Frédéric Houssiau, Brussels (BE)
- 14.50 **I46** **The long road to complete remission of lupus nephritis**
Ana Malvar, Buenos Aires (AR)
- 15.10 **I47** **Repeat kidney biopsy to guide treatment?**
Ioannis Parodis, Stockholm (SE)
- 15.30 **O37** **Persistence of urinary biomarkers of intrarenal inflammation precedes loss of kidney function in lupus nephritis**
Andrea Fava, Baltimore (US)
- 15.40 **O38** **Immune deposit resorption in per-protocol repeat kidney biopsy performed in patients with proliferative lupus nephritis**
Nursen Cetrez, Stockholm (SE)
- 15.50 **O39** **Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: A systematic review and meta-analysis of the standard of care arms of randomized controlled trials**
Ali Duarte, Rochester (US)
- 16.00 **Coffee Break**
- 16.30 **Fishbowls I - IV**
- 17.15 **Fishbowl V - VIII**
- 18.00 **End of day 2**
- 19.30 **Congress Dinner**

Chamber Music Room

Session 16: Patients' Session - What really matters for Patients?

- 14.30 **I48** **Management of fatigue**
Laurent Arnaud, Strasbourg (FR) & Ida Povilaite (Lupus Europe)
- 14.55 **I49** **Quality of life and disease burden**
Marta Mosca, Pisa (IT) & Dalila Tremarias (Lupus Europe)
- 15.20 **I50** **Shared decision making**
Matthias Schneider, Düsseldorf (DE) & Jeanette Andersen (Lupus Europe)
- 15.45 **O40** **ChatSLE - Consulting ChatGPT for 100 frequently asked lupus questions**
Isabell Haase, Hamburg (DE)
- 15.55 **O41** **Patients with systemic lupus erythematosus experience poor health-related quality of life despite a low disease activity state or remission**
Ioannis Parodis, Stockholm (SE)
- 16.00 **Coffee Break**
- 16.30 **Fishbowls I - IV**
- 17.15 **Fishbowls V - VIII**
- 18.00 **End of day 2**
- 19.30 **Congress Dinner**

07.45 **SLEuro General Assembly**

08.45 Satellite Symposium

Parallel Sessions 17 & 18

Session 17: Treatment of Nephritis II

Concert Hall

- 09.15 **I51** **Is lupus nephritis treatment different in Latin America?**
Bernardo Pons-Estel, Rosario (AR)
- 09.35 **I52** **Discontinuation of maintenance therapy**
Eric Daugas, Paris (FR)
- 09.55 **I53** **CKD therapy**
Hans-Joachim Anders, München (DE)
- 10.15 **O42** **Three years is the minimal effective duration of sustained clinical remission associated with reduced risk of impaired kidney function and of damage accrual in lupus nephritis**
Mariele Gatto, Turin (IT)
- 10.25 **O43** **Long-term outcomes of chronic kidney disease patients with lupus nephritis: A nationwide cohort study**
Francesca Faustini, Stockholm (SE)
- 10.35 **Coffee Break**
- 11.00 Satellite Symposium

07.45 **SLEuro General Assembly**

08.45 Satellite Symposium

Session 18: Pathophysiology

Chamber Music Room

- 09.15 **I54** **Navigating the complexities of lupus pathogenesis: novel players and targets for improved treatment**
Nan Shen, Shanghai (CN)
- 09.35 **I55** **Platelets in SLE**
Patrick Blanco, Bordeaux (FR)
- 09.55 **I56** **When DNA loses nuclear control**
Martin Herrmann, Erlangen (DE)
- 10.15 **O44** **Of mice and men: Using humanised HLA transgenic mouse models to explore the role of HLA in systemic lupus erythematosus**
Thuvaraka Ware, London (UK)
- 10.25 **O45** **Distinct modular transcriptomic signatures associate with symptomatic fatigue and pain in ANA+ subjects both with and without clinically evolving SLE**
Lucy Marie Carter, Leeds (UK)
- 10.35 **Coffee Break**
- 11.00 Satellite Symposium
- 11.30 **Great Debate** **Concert Hall**
A minority of lupus patients (will) need a biologic
Michelle Petri, Baltimore (US)
- A majority of lupus patients (will) need a biologic**
David Isenberg, London (UK)
- 12.30 **Closing Ceremony**
- 12.45 **Light Lunch**

Sponsors

Diamond Sponsor



Platinum Sponsor



White Gold Sponsor



Gold Sponsor



Silver Sponsor



Bronze Sponsor

